Published in J Antimicrob Chemother on December 09, 2014
The Individualized M(X) Drug-resistant TB Treatment Strategy Study (InDEX) | NCT03237182
Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Med (2015) 1.21
Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform. Clin Infect Dis (2015) 1.02
Utility of Whole-Genome Sequencing of Escherichia coli O157 for Outbreak Detection and Epidemiological Surveillance. J Clin Microbiol (2015) 0.87
Methodological and Clinical Aspects of the Molecular Epidemiology of Mycobacterium tuberculosis and Other Mycobacteria. Clin Microbiol Rev (2016) 0.84
Clinical use of whole genome sequencing for Mycobacterium tuberculosis. BMC Med (2016) 0.83
Diagnostic 'omics' for active tuberculosis. BMC Med (2016) 0.82
Rapid Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study. J Clin Microbiol (2016) 0.77
High rate of drug resistance among tuberculous meningitis cases in Shaanxi province, China. Sci Rep (2016) 0.75
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates. Antimicrob Agents Chemother (2016) 0.75
Whole-Genome Sequencing of Bacterial Pathogens: the Future of Nosocomial Outbreak Analysis. Clin Microbiol Rev (2017) 0.75
A joint cross-border investigation of a cluster of multidrug-resistant tuberculosis in Austria, Romania and Germany in 2014 using classic, genotyping and whole genome sequencing methods: lessons learnt. Euro Surveill (2017) 0.75
Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N Engl J Med (2011) 7.35
Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis (2012) 7.18
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis (2010) 5.14
Tuberculosis drug resistance mutation database. PLoS Med (2009) 4.13
Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet (2014) 3.49
Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak: a longitudinal molecular epidemiological study. PLoS Med (2013) 3.02
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J (2012) 2.61
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother (2012) 2.26
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J (2012) 2.17
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother (2012) 2.16
Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One (2012) 1.93
Evaluation of mycobacteria growth indicator tube for direct and indirect drug susceptibility testing of Mycobacterium tuberculosis from respiratory specimens in a Siberian prison hospital. J Clin Microbiol (2001) 1.85
The tempo and mode of molecular evolution of Mycobacterium tuberculosis at patient-to-patient scale. Infect Genet Evol (2009) 1.76
Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis (2013) 1.69
Whole genome sequencing analysis of intrapatient microevolution in Mycobacterium tuberculosis: potential impact on the inference of tuberculosis transmission. J Infect Dis (2013) 1.61
Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J (2012) 1.54
Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother (2009) 1.52
New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One (2012) 1.49
Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. MMWR Recomm Rep (2009) 1.48
Population structure of multi- and extensively drug-resistant Mycobacterium tuberculosis strains in South Africa. J Clin Microbiol (2011) 1.29
Mycobacterium tuberculosis thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA deletion confers resistance to p-aminosalicylic acid. Microbiology (2011) 1.23
Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother (2013) 1.19
Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74. Antimicrob Agents Chemother (2010) 1.01
Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance. Antimicrob Agents Chemother (2011) 0.98
Role of the dihydrofolate reductase DfrA (Rv2763c) in trimethoprim-sulfamethoxazole (co-trimoxazole) resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2010) 0.88